Celltrion, Inc.
Celltrion is a South Korean biopharmaceutical company engaged in biologic medicine development, manufacture and commercialization. Its operations include antibody therapeutics and biosimilars, with ongoing pharmaceutical research relevant to autoimmune diseases, oncology and other inflammatory conditions. As a large biologics developer, Celltrion integrates analytical, process and clinical capabilities with global marketing partnerships. The company is listed on the KOSPI market under code 068270 and is based in Incheon, South Korea. This directory represents the listed pharmaceutical issuer rather than treating individual subsidiary brands or distribution arrangements as separate issuers.
Company at a glance
Corporate information
- Company entity
- Celltrion, Inc.
- Headquarters / principal office
- South Korea
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.celltrion.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
KOSPI: 068270
antibody biologics · biosimilars · therapeutic development
autoimmune diseases · oncology · inflammatory disorders
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Celltrion is a South Korean biopharmaceutical company engaged in biologic medicine development, manufacture and commercialization. Its operations include antibody therapeutics and biosimilars, with ongoing pharmaceutical research relevant to autoimmune diseases, oncology and other inflammatory conditions. As a large biologics developer, Celltrion integrates analytical, process and clinical capabilities with global marketing partnerships. The company is listed on the KOSPI market under code 068270 and is based in Incheon, South Korea. This directory represents the listed pharmaceutical issuer rather than treating individual subsidiary brands or distribution arrangements as separate issuers.
Business, technology & evidence
- SecuritiesKOSPI: 068270
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Celltrion, Inc. ↗Celltrion, Inc. ·
- Official issuer and R&D disclosure · Celltrion, Inc. ↗Celltrion, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.